Characteristics and food consumption for current, previous, and potential consumers of GLP-1 s

Widespread adoption of Glucagon-like peptide-1 (GLP-1) agonists could cause significant changes in food consumption and preferences that disrupt the food industry. In this study, we survey four consumer groups to better understand how GLP-1 s may affect food consumption and preferences. The four groups were: 1) consumers currently using a GLP-1, 2) consumers who have previously used a GLP-1, 3) consumers who haven't used a GLP-1 but plan to in the future, and 4) consumers who haven't used a GLP-1 and don't plan to in the future. Results show that consumers currently taking a GLP-1 consume significantly fewer calories than the other groups surveyed, and calorie reduction while taking a GLP-1 for weight loss could be around 720 to 990 cal. Additionally, those taking GLP-1 s most likely reduce consumption of processed foods, sugar-sweetened beverages, refined grains, and beef. The results of this study will inform potential consumers and food companies of valuable insights into the broader effects of GLP-1 s on caloric intake and food preferences. • The consumer market for Glucagon-like peptide-1 (GLP-1) agonists is significant. • We surveyed four consumer groups, including those who had or are taking a GLP-1. • Gender, household size, and education were associated with GLP-1 use and interest. • Intake recall suggests that GLP-1 users reduce consumption more than 700 cal. • GLP-1 users reduced consumption of processed foods, soda, refined grains, and beef.